DE69522012T2 - Karzinombehandlung - Google Patents

Karzinombehandlung

Info

Publication number
DE69522012T2
DE69522012T2 DE69522012T DE69522012T DE69522012T2 DE 69522012 T2 DE69522012 T2 DE 69522012T2 DE 69522012 T DE69522012 T DE 69522012T DE 69522012 T DE69522012 T DE 69522012T DE 69522012 T2 DE69522012 T2 DE 69522012T2
Authority
DE
Germany
Prior art keywords
cancer treatment
treatment
carcinomas
inducer
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69522012T
Other languages
English (en)
Other versions
DE69522012D1 (de
Inventor
Sterling Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Birmingham
Original Assignee
University of Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Birmingham filed Critical University of Birmingham
Application granted granted Critical
Publication of DE69522012D1 publication Critical patent/DE69522012D1/de
Publication of DE69522012T2 publication Critical patent/DE69522012T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69522012T 1994-12-13 1995-12-01 Karzinombehandlung Expired - Lifetime DE69522012T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9425060.2A GB9425060D0 (en) 1994-12-13 1994-12-13 Carcinoma treatment
PCT/GB1995/002807 WO1996018413A1 (en) 1994-12-13 1995-12-01 Carcinoma treatment

Publications (2)

Publication Number Publication Date
DE69522012D1 DE69522012D1 (de) 2001-09-06
DE69522012T2 true DE69522012T2 (de) 2002-04-25

Family

ID=10765814

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69522012T Expired - Lifetime DE69522012T2 (de) 1994-12-13 1995-12-01 Karzinombehandlung

Country Status (12)

Country Link
EP (1) EP0806963B1 (de)
JP (1) JP4076230B2 (de)
AT (1) ATE203676T1 (de)
AU (1) AU691996B2 (de)
CA (1) CA2207779C (de)
DE (1) DE69522012T2 (de)
FI (1) FI118918B (de)
GB (1) GB9425060D0 (de)
MX (1) MX9704372A (de)
NO (1) NO318587B1 (de)
NZ (1) NZ296161A (de)
WO (1) WO1996018413A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09507074A (ja) * 1993-12-23 1997-07-15 イミュネックス・コーポレーション Ｃｄ４０を発現する腫瘍細胞を特徴とする疾患の予防又は治療方法
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
EA004107B1 (ru) 1998-08-11 2003-12-25 Айдек Фармацевтикалс Корпорэйшн Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US7138379B2 (en) * 2000-07-26 2006-11-21 Schering Aktiengesellschaft Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons
GB0025132D0 (en) * 2000-10-13 2000-11-29 Medical Res Council Method
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
CA2544852A1 (en) * 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
CA2609269C (en) 2005-05-26 2014-08-05 Seattle Genetics, Inc. Humanized anti-cd40 antibodies and their methods of use
KR20080073725A (ko) 2005-11-01 2008-08-11 노파르티스 아게 항-ｃｄ40 항체의 용도
PT2540820T (pt) 2005-12-09 2018-03-02 Academisch Medisch Centrum Bij De Univ Van Amsterdam Meios e métodos para influenciar a establidade de células produtoras de anticorpos
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
WO2007124299A2 (en) 2006-04-21 2007-11-01 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
MX2010005080A (es) 2007-11-07 2010-07-28 Genentech Inc Metodos y composiciones para determinar la sensibilidad de linfoma de celula b al tratamiento con anticuerpos anti-cd40.
CN102459639A (zh) 2009-04-18 2012-05-16 健泰科生物技术公司 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法
JP5781508B2 (ja) 2009-07-15 2015-09-24 アイム・セラピューティクス・べー・フェー 高親和性抗体を産生させるための手段および方法
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
CN103429615B (zh) 2010-12-02 2018-03-16 埃姆医疗有限公司 用于生产高亲和力抗体的方式和方法
JP6125489B2 (ja) 2011-04-29 2017-05-10 アペクシジェン， インコーポレイテッド 抗ｃｄ４０抗体および使用方法
AU2013337903B2 (en) 2012-10-30 2018-08-16 Apexigen, Inc. Anti-CD40 antibodies and methods of use
EP3099709B1 (de) 2014-01-31 2019-12-25 AIMM Therapeutics B.V. Mittel und verfahren zur herstellung von stabilen antikörpern

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
CA2207779A1 (en) 1996-06-20
JPH10510526A (ja) 1998-10-13
FI118918B (fi) 2008-05-15
CA2207779C (en) 2009-10-06
ATE203676T1 (de) 2001-08-15
NO972732D0 (no) 1997-06-13
MX9704372A (es) 1998-02-28
WO1996018413A1 (en) 1996-06-20
AU691996B2 (en) 1998-05-28
NO318587B1 (no) 2005-04-11
EP0806963B1 (de) 2001-08-01
DE69522012D1 (de) 2001-09-06
GB9425060D0 (en) 1995-02-08
AU3988495A (en) 1996-07-03
FI972484A0 (fi) 1997-06-12
NZ296161A (en) 2001-10-26
FI972484A (fi) 1997-06-12
EP0806963A1 (de) 1997-11-19
JP4076230B2 (ja) 2008-04-16
NO972732L (no) 1997-06-13

Similar Documents

Publication Publication Date Title
DE69522012T2 (de) Karzinombehandlung
ES8100457A1 (es) Perfeccionamientos en los dispositivos de borde iluminado
DE3786205D1 (de) Titanocene und deren verwendung.
TR200000726T2 (tr) Budesonid ve formoterol'ün yeni kullanımı.
DE69115182D1 (de) Polymerzusammensetzung und ihre Verwendung.
PT935465E (pt) Compostos novos de imidazole substituido
MXPA02001726A (es) Celda de combustible y placa bipolar para utilizarse con la misma.
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
TR199701212T1 (xx) �drar� tutamama halinin tedavisi i�in alfa IL- agonistlerinin kullan�lmas�.
EP0492248A3 (en) Intumescent sheet, its manufacture and use
DE69723863D1 (de) Chinoline und deren therapeutische verwendung
IT1285770B1 (it) Composti corticoidei
ES292314U (es) Un articulo sanitario
DE69914357D1 (de) Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
TW355847B (en) A surface treatment steel plate used for battery case, batterycase and battery using the case
YU45591A (sh) Novi retinoidi
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
DE3674079D1 (de) Bindercopolymerzusammensetzung und damit behandelte papiere.
NO902532L (no) Fremgangsmaate for fremstilling av flytebro, samt flytebrofortrinnsvis fremstillet i henhold til fremgangsmaaten.
AU9758898A (en) (in situ)-generated solid radiation source based on tungsten188/rhenium188 and the use thereof
ZA972776B (en) 4-[(thien-2-yl)methyl]-imidazole analgesics
TR200002939T2 (tr) Paroksetin maleat
ES8504419A1 (es) Procedimiento para la sensibilizacion al calor de dispersiones acuosas de polimero.
DE59106847D1 (de) Überzugsmittel sowie dessen Verwendung.
DE59400924D1 (de) Beta-Hydroxyoximether und bei Raumtemperatur mit beta-Hydroxyoximethern vernetzbare Dispersionen oder Lösungen